- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01945645
Ready to Act - Health Education in People With Hyperglycaemia
September 14, 2013 updated by: University of Aarhus
Ready to Act. A Health Education Programme for People With Screen-detected Hyperglycaemia
A pre-randomized study in primary health care was designed to investigate health education in a subpopulation extracted from general practitioners (GPs) in one Danish county in the treatment arm of the ADDITION (Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care) study, DK.
The overall objective of the 'Ready to Act' health education programme was to support the participants' competences in daily life and act appropriately with respect to their dysglycaemic condition.
The achievement of action competence involved four learning objectives: intrinsic motivation, informed decision-making, action experience and social involvement.
The programme was delivered in primary care settings (health centre or GP surgeries) by nurses, dieticians, physiotherapists and GPs.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
509
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aarhus, Denmark
- Department of Public Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 69 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age 40-69 years at the time of screening and diagnosed with screen-detected T2D, IGT or IFG (according to WHO criteria).
Exclusion Criteria:
- women who were pregnant or lactating, those with a psychotic illness or an illness with a prognosis of less than one year.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy.
The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
|
The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy.
The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modelled cardiovascular disease risk
Time Frame: 3 years after intervention, dec 2010
|
The risk is measured by a SCORE model uses information on age, sex, smoking status, total cholesterol and systolic blood pressure.
It provides an estimate of ten-year fatal cardiovascular disease risk
|
3 years after intervention, dec 2010
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycated hemoglobin
Time Frame: 3 years after intervention, dec 2010
|
Glycated hemoglobin (HbA1c)is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time
|
3 years after intervention, dec 2010
|
|
se-cholesterol
Time Frame: 3 years after intervention, dec 2010
|
Serum cholesterol is the total amount of cholesterol found in the blood.
|
3 years after intervention, dec 2010
|
|
Patient Activation
Time Frame: One year and three year (2006, 2007, 2010)
|
The Patient Activation Measure (PAM-13) is a composite measure of perceived skills, self-efficacy and knowledge.
|
One year and three year (2006, 2007, 2010)
|
|
Blood pressure
Time Frame: 3 years after intervention, dec 2010
|
Systolic and diastolic blood pressure were measured
|
3 years after intervention, dec 2010
|
|
Physical activity
Time Frame: 3 years after intervention, dec 2010
|
Physical activity was measured using the International Physical Activity questionnaire (IPAQ-short form)
|
3 years after intervention, dec 2010
|
|
Smoking
Time Frame: 3 years after intervention, 2010
|
Smoking status was assessed by standard questions.
|
3 years after intervention, 2010
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Helle Terkildsen Maindal, MPH, PhD, Aarhus University, Department of Public Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
September 14, 2013
First Submitted That Met QC Criteria
September 14, 2013
First Posted (Estimate)
September 18, 2013
Study Record Updates
Last Update Posted (Estimate)
September 18, 2013
Last Update Submitted That Met QC Criteria
September 14, 2013
Last Verified
September 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ready to Act
- 20000183 (Ethical approval)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaboratorsNot yet recruitingType 2 Diabetes | Diabetes Mellitus Type 2Turkey (Türkiye)
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Steno Diabetes Center CopenhagenRecruitingDiabetes | Cognitive Impairment | Type 2 Diabetes | Diabetes Mellitus Type 2 | Cognitive Decline | Type 2 Diabetes Mellitus (T2DM)Denmark
Clinical Trials on Ready to act
-
Texas Tech UniversityEHP LabsCompletedMetabolism | Metabolic RateUnited States
-
Abbott NutritionCompletedHospitalized ElderlyUnited States, Puerto Rico
-
Temple UniversityUniversity of Florida; University of Minnesota; University of New HampshireNot yet recruitingDevelopmental Disability | Intellectual Disability, Mild to ModerateUnited States
-
University of British ColumbiaActive Aging Society; Specialist Services Committee (Doctors of BC)RecruitingPain | Osteoarthritis | Osteoarthritis, Hip | Mobility Limitation | Implementation Science | Physical Inactivity | Osteoarthritis (OA) of the Knee | Total Knee Arthroplasty; Total Hip Arthroplasty | Sedentary Behaviors | Social Isolation or LonelinessCanada
-
University of South CarolinaNational Institute of General Medical Sciences (NIGMS)Completed
-
Harokopio UniversityCompletedDiabetes Mellitus, Type 2Greece
-
Colorado State UniversityThrasher Research Fund; Savica, Indonesia; Institute of Research for Development...CompletedSevere Acute MalnutritionIndonesia
-
Tuberculosis Research Centre, IndiaLondon School of Hygiene and Tropical Medicine; Queen Mary University of London and other collaboratorsActive, not recruitingTuberculosis | Malnutrition, ChildIndia
-
University of Nebraska LincolnCenters for Disease Control and Prevention; The Set Me Free Project; Des Moines...CompletedSexual Violence | Sex Trafficking | Child Abuse, Sexual | Sex Crimes | Commercial Sex | Sex OffenseUnited States
-
Makerere UniversityNUFUUnknownMalnutritionNorway, Uganda